Cellular and Molecular Life Sciences · 2019 · 41 citations · 39 references
MedicineImmunologyOncologyCancer ImmunologyTranscriptional RegulationTumor MicroenvironmentCancer ImmunotherapyEpigenetic Regulation In CancerImmune Checkpoint ModulationImmune Checkpoint RegulationImmune CheckpointsT Cell ExhaustionCheckpoint Modulation In CancerEpigenetic RegulationImmune Checkpoint ResistanceImmune Checkpoint Signaling PathwaysImmunosuppressive MicroenvironmentT Cell Checkpoint InhibitionTerminally Exhausted T CellsTumor Microenvironment Effects
The elevated expression of immune checkpoints by the tumor microenvironment is associated with poor prognosis in several cancers due to the exhaustion of tumor-infiltrating lymphocytes (TILs), and the effective suppression of the expression of these genes is key to reversing the exhaustion of TILs. Herein, we determined that serine/arginine-rich splicing factor 2 (SRSF2) is a target for blocking the tumor microenvironment-associated immunosuppressive effects. We found that the expression of SRSF2 was increased in exhausted T cells and that SRSF2 was involved in multiple immune checkpoint molecules mediating TILs' exhaustion. Furthermore, SRSF2 was revealed to regulate the transcription of these immune checkpoint genes by associating with an acyl-transferases P300/CBP complex and altering the H3K27Ac level near these genes, thereafter influencing the recruitment of signal transducer and activator of transcription 3 (STAT3) to these gene promoters. Collectively, our data indicated that SRSF2 functions as a modulator of the anti-tumor response of T cells and may be a therapeutic target for reversing the exhaustion of TILs.
39
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations
Medicine, Oncology, Pharmacotherapy +13
Ahmedin Jemal, Anish Thomas, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2002 · 2.9K citations · Full text
Medicine, Demography, Oncology +17